Details for Patent: 7,335,799
✉ Email this page to a colleague
Which drugs does patent 7,335,799 protect, and when does it expire?
Patent 7,335,799 protects NEXLETOL and NEXLIZET and is included in two NDAs.
This patent has twenty-three patent family members in thirteen countries.
Summary for Patent: 7,335,799
| Title: | Hydroxyl compounds and compositions for cholesterol management and related uses |
| Abstract: | The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. |
| Inventor(s): | Dasseux; Jean-Louis Henri (Brighton, MI), Oniciu; Carmen Daniela (Ann Arbor, MI) |
| Assignee: | Esperion Therapeutics, Inc. (Ann Arbor, MI) |
| Application Number: | 10/743,470 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 7,335,799
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esperion Theraps Inc | NEXLETOL | bempedoic acid | TABLET;ORAL | 211616-001 | Feb 21, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,335,799
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2404890 | ⤷ Sign Up | 301062 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2404890 | ⤷ Sign Up | LUC00174 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2404890 | ⤷ Sign Up | 122020000048 | Germany | ⤷ Sign Up |
| European Patent Office | 2404890 | ⤷ Sign Up | 132020000000112 | Italy | ⤷ Sign Up |
| European Patent Office | 2404890 | ⤷ Sign Up | 2020C/534 | Belgium | ⤷ Sign Up |
| European Patent Office | 2404890 | ⤷ Sign Up | CA 2020 00041 | Denmark | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
